• Publications
  • Influence
Chitosan
TLDR
The totality of the meaningful information (including key unpublished data) supporting the development of chitosan-adjuvanted vaccines is summarized.
PecSys: in situ gelling system for optimised nasal drug delivery
TLDR
The lead product using PS is a fentanyl nasal spray formulation (NasalFent®), which has successfully met the primary objective in a pivotal Phase III clinical study and is scheduled for regulatory filings in the first half of 2009.
Transdermal Delivery of Interferon Alpha-2B using Microporation and Iontophoresis in Hairless Rats
TLDR
Iontophoresis enhanced delivery through microporated skin in hairless rats resulted in a two-fold increase in the dose delivered in the hairless rat, and in vivo delivery of IFNα2b was demonstrated throughmicropores created in the outer layer of the skin.
Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip
TLDR
In vivo, this enhancement of retention will provide optimum patient acceptability, modulate drug absorption and maximize the ability of drugs to be absorbed across the nasal mucosa and thus reduce variability in drug delivery.
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
TLDR
Real-world evidence (RWE) from 10 clinical ALS databases indicates that riluzole therapy may afford much greater extension of survival, and improvements in median survival times of more than 19 months have been reported in the overall ALS patient population.
...
...